Logo do repositório
 
Publicação

How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care

2026-04Recensão Acesso aberto
Ver registo simples
dc.contributor.authorCaetano, Joana
dc.contributor.authorPires, Ana Marta
dc.contributor.authorCosta, Carlos
dc.contributor.authorBergantim, Rui
dc.contributor.authorRoque, Adriana
dc.contributor.authorFerraz, Patrícia
dc.contributor.authorCunha, Maria Rosário
dc.contributor.authorBolli, Niccolo
dc.contributor.authorPuig, Noemi
dc.contributor.authorJoão, Cristina
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2026-05-05T14:15:01Z
dc.date.available2026-05-05T14:15:01Z
dc.date.issued2026-04
dc.descriptionPublisher Copyright: © 2026 by the authors.
dc.description.abstractMultiple myeloma is a complex hematologic malignancy characterized by significant biological heterogeneity, a relapsing–remission clinical course, and a continuously evolving therapeutic landscape. Accurate and timely laboratory assessment is central to disease management, supporting diagnosis, risk stratification, evaluation of treatment response, and long-term monitoring. Despite major advances in therapy, a critical need remains for laboratory tools that can detect disease with greater sensitivity, capture spatial and clonal tumor heterogeneity, and reflect the true depth of treatment response beyond conventional serological and bone marrow-based criteria. Recent laboratory innovations have the potential to transform myeloma care by enabling earlier detection, more accurate prognostication, and personalized therapeutic strategies. This review focuses specifically on innovative laboratory technologies for the diagnosis of multiple myeloma and the evaluation of treatment response. Within this scope, we examine the current diagnostic approaches and the role of high-throughput technologies for measurable residual disease assessment. We explore the emerging role of liquid biopsy approaches, including circulating tumor cells, cell-free DNA/RNA, and mass spectrometry for ultrasensitive detection of monoclonal proteins. We further discuss novel molecular biomarkers and the integration of artificial intelligence and machine learning tools to enhance data interpretation. The innovations reviewed here represent a shift in the contribution of laboratory medicine to myeloma care, offering a more precise, less invasive, and biologically informative framework for targeted and adaptive clinical decisions.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1839880
dc.identifier.doi10.3390/cancers18081275
dc.identifier.issn2072-6694
dc.identifier.otherPURE: 161877610
dc.identifier.otherPURE UUID: 0ebe6a6b-96bf-4faa-abc2-bec695b8a3af
dc.identifier.otherScopus: 105037090196
dc.identifier.urihttp://hdl.handle.net/10362/202842
dc.identifier.urlhttps://www.scopus.com/pages/publications/105037090196
dc.language.isoeng
dc.peerreviewedyes
dc.subjectartificial intelligence
dc.subjectcell-free DNA
dc.subjectcirculating tumor cells
dc.subjectdiagnosis
dc.subjectmass spectrometry
dc.subjectmeasurable residual disease
dc.subjectmultiple myeloma
dc.subjectprognosis
dc.subjectOncology
dc.subjectCancer Research
dc.subjectSDG 3 - Good Health and Well-being
dc.titleHow Laboratory Innovations Are Shaping the Future of Multiple Myeloma Careen
dc.typereview
degois.publication.issue8
degois.publication.titleCancers
degois.publication.volume18
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
cancers-18-01275.pdf
Tamanho:
1.75 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica